Tissue Perfusion and Blood Flow Monitoring Technology

描述(由申请人提供)：需要能够量化组织灌注量，以评估诸如伤口和皮瓣等缺血组织的生存能力。对于糖尿病患者的伤口护理，早期发现血管生成障碍是抢救的重要决定因素。这降低了成本，降低了截肢风险，并提高了患者满意度。约10%的皮瓣需要翻修，打捞成功率约为85%。有效的皮瓣监测将为皮瓣手术可能出现的并发症提供早期预警，并使早期干预成为可能。目前，对于移植物和创面的改善和评价，仍多采用主观目视观察。基于激光散斑空间分析的成像仪将作为一个独立的单元来开发。该方法使用动态事件的空间平均来获得来自一次曝光的速度图像的全局图像。可以使用在不同曝光下从同一场景获得的图像来提高速度值的准确性。它允许实时获取全场灌注图像。较短的曝光时间会减少运动伪影的影响。随着美国人口中肥胖率越来越高，出现了更多的糖尿病病例。建议的激光散斑成像仪提供了对接受高压氧治疗和/或手术的患者的组织活力的实时非侵入性监测。它可以减少与修订皮肤移植相关的财务成本和对医务人员的体力要求，并通过确定继续高压氧治疗的有效性。在临床试验后，其商业市场和应用将更加明显。从这个项目中获得的科学、技术和临床知识可以用来改进高压氧治疗方案，降低治疗成本和时间。根据疾病控制和预防中心的数据，总共有2,080万人患有糖尿病，占美国人口的7%。据估计，2002年美国的糖尿病成本为1,320亿美元，约占医疗保健总支出的11%。该项目旨在开发一种先进的、非接触和非侵入性的光学成像仪，以提供对糖尿病患者选定伤口区域的血流速度的实时、定量测量。

DESCRIPTION (provided by applicant): There is a need to be able to quantify tissue perfusion for the purpose of assessing the viability of ischemic tissue such as wounds and flaps. For wound care in diabetes, early detection of angiogenesis compromise is an important determinant of salvage. This reduces cost, reduces risk of amputation, and increases patient satisfaction. Approximately 10% of all flaps require revision with a salvage rate of approximately 85%. Effective monitoring flaps would provide early warning of possible complications for flap surgery and allow earlier intervention. Currently subjective visual observation is still commonly used to identify the improvement and assessment of grafts and wounds. An imager based on the spatial analysis of laser speckle will be developed as a standalone unit. This method employs spatial averaging of the dynamic events to obtain a global picture of the velocity image from one exposure. Images obtained from the same scene at different exposures can be used to improve accuracy of the velocity values. It allows acquisition of full-field perfusion images in real time. The short exposure time reduces the effects of motion artifacts. W with an increasingly high percentage of obesity in the U.S. population, more diabetic cases have emerged. The proposed laser speckle imager provides real-time noninvasive monitoring of tissue viability in patients undergoing hyperbaric oxygen therapy and/or surgery. It can reduce the financial costs and physical demands on the medical staff associated with the revision of skin grafts and by determining the effectiveness of continued HBO treatment. Its commercial marketability and application will become more apparent after the clinical trial. The scientific, technical, and clinical knowledge gained from this project can be utilized to improve protocols for hyperbaric oxygen therapy, reducing both costs and time of treatment. According to the Centers for Disease Control and Prevention, a total of 20.8 million people or 7% of the U.S. population have diabetes. The estimated diabetes cost in the U.S. in 2002 was $132 billion, about 11% of the total health care expenditure. This project is designed to develop an advanced, noncontact, and noninvasive optical imager to provide real-time, quantitative measurements of blood velocities in the selected wound areas of diabetic patients.